Clinical trials: Etoposide, completed
Extranodal NK-T-Cell Lymphoma, Nasal Type
GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, etoposide, pegaspargase and dexamethasone (GELAD) chemotherapy and sandwiched radiotherapy as first-line treatment in patients with de novo stage…
- Trial name
- NCT02733458
- Testing
- GELAD, Radiotherapy
- Where
- 7 sites in China
- Volunteers
- 52 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00007865
- Testing
- rituximab, carboplatin, etoposide
- Where
- United States
- Sponsor
- University of Nebraska
Lymphoma
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- ALCL 99 (NCT00006455)
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 885 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC
ML Decision Model for G-NEC Adjuvant Therapy
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis.
- Conditions
- Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC, Survival Outcomes, Machine Learning
- Trial name
- G-NEC (NCT06663852)
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- Chang-Ming Huang, Prof.
Leukemia
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00096135
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 153 sites in United States, Australia and 3 more
- Volunteers
- 168 people
- Sponsor
- Children's Oncology Group
Non-small Cell Lung Cancer
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
- Trial name
- CHORUS (NCT04905316)
- Testing
- Canakinumab, Durvalumab, Radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder…
- Conditions
- Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Trial name
- DA-EPOCH-R (NCT01760226)
- Testing
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Leukemia
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or…
- Trial name
- NCT00844298
- Testing
- Nilotinib+mVPD
- Where
- 16 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- Asan Medical Center
Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004169
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003631
- Testing
- filgrastim, carboplatin, carmustine
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Bone Marrow Transplantation in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for…
- Trial name
- NCT00002829
- Testing
- Recombinant Interferon Alfa, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Extensive-stage Small Cell Lung Cancer
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
This is a single-arm Phase Ib/II multicenter open-label study, with translational sub-study, of atezolizumab plus autologous dendritic cell vaccine as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- VENEZO-LUNG (NCT04487756)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, ADC Vaccine, Carboplatin
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto Oncológico Dr Rosell
Acute Myelogenous Leukemia
Lenalidomide Plus Chemotherapy for AML
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01681537
- Testing
- Lenalidomide, Mitoxantrone, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Hodgkin's Lymphoma
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent…
- Trial name
- NCT00352027
- Testing
- Adriamycin®, Vinblastine, Nitrogen Mustard
- Where
- 6 sites in United States
- Volunteers
- 81 people
- Sponsor
- St. Jude Children's Research Hospital
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT02561273
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Nebraska